• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于具有位置和尺度变化备择假设的两样本问题的非参数检验和广义检验。

On non-parametric and generalized tests for the two-sample problem with location and scale change alternatives.

作者信息

Podgor M J, Gastwirth J L

机构信息

Division of Biometry and Epidemiology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.

出版信息

Stat Med. 1994;13(5-7):747-58. doi: 10.1002/sim.4780130535.

DOI:10.1002/sim.4780130535
PMID:8023047
Abstract

Various tests have been proposed for the two-sample problem when the alternative is more general than a simple shift in location: non-parametric tests; O'Brien's generalized t and rank sum tests; and other tests related to the t. We show that the generalized tests are directly related to non-parametric tests proposed by Lepage. As a result, we obtain a wider, more flexible class of O'Brien-type procedures which inherit the level robustness property of non-parametric tests. We have also computed the tests' empirical sizes and powers under several models. The non-parametric procedures and the related O'Brien-type tests are valid and yield good power in the settings investigated. They are preferable to the t-test and related procedures whose type I errors differ noticeably from nominal size for skewed and long-tailed distributions.

摘要

当备择假设比位置上的简单偏移更一般时,针对双样本问题已经提出了各种检验方法:非参数检验;奥布赖恩广义t检验和秩和检验;以及其他与t检验相关的检验。我们表明,这些广义检验与勒佩奇提出的非参数检验直接相关。因此,我们得到了一类更广泛、更灵活的奥布赖恩型程序,它们继承了非参数检验的水平稳健性。我们还计算了在几种模型下这些检验的经验大小和功效。在所研究的设置中,非参数程序和相关的奥布赖恩型检验是有效的,并且具有良好的功效。对于偏态和长尾分布,它们比t检验及相关程序更可取,因为后者的I型错误与名义大小有明显差异。

相似文献

1
On non-parametric and generalized tests for the two-sample problem with location and scale change alternatives.关于具有位置和尺度变化备择假设的两样本问题的非参数检验和广义检验。
Stat Med. 1994;13(5-7):747-58. doi: 10.1002/sim.4780130535.
2
The appropriateness of the Wilcoxon test in ordinal data.威尔科克森检验在有序数据中的适用性。
Stat Med. 1996 Mar 30;15(6):631-45. doi: 10.1002/(SICI)1097-0258(19960330)15:6<631::AID-SIM206>3.0.CO;2-6.
3
A rank-based sample size method for multiple outcomes in clinical trials.一种用于临床试验中多结局的基于秩的样本量方法。
Stat Med. 2008 Jul 20;27(16):3084-104. doi: 10.1002/sim.3182.
4
Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem.调整奥布赖恩检验以控制广义非参数贝伦斯-费希尔问题的I型错误。
Biometrics. 2005 Jun;61(2):532-9. doi: 10.1111/j.1541-0420.2005.00322.x.
5
Practical usage of O'Brien's OLS and GLS statistics in clinical trials.奥布赖恩普通最小二乘法(OLS)和广义最小二乘法(GLS)统计量在临床试验中的实际应用。
Pharm Stat. 2008 Jan-Mar;7(1):53-68. doi: 10.1002/pst.268.
6
Two sample comparisons including zero-inflated continuous data: A parametric approach with applications to microarray experiment.零膨胀连续数据的两样本比较:一种参数方法及其在微阵列实验中的应用。
Math Biosci. 2018 Apr;298:19-28. doi: 10.1016/j.mbs.2018.01.009. Epub 2018 Feb 10.
7
Some power considerations when deciding to use transformations.决定使用变换时的一些功率考量因素。
Stat Med. 1994;13(5-7):769-83. doi: 10.1002/sim.4780130537.
8
Flexible designs by adaptive plans of generalized Pocock- and O'Brien-Fleming-type and by self-designing clinical trials.通过广义Pocock型和O'Brien-Fleming型适应性计划以及自行设计的临床试验实现的灵活设计。
Biom J. 2006 Aug;48(4):521-36. doi: 10.1002/bimj.200510212.
9
Investigation Into the Effects of Using Normal Distribution Theory Methodology for Likert Scale Patient-Reported Outcome Data From Varying Underlying Distributions Including Floor/Ceiling Effects.采用正态分布理论方法对具有底层/天花板效应的不同潜在分布的利克特量表患者报告结局数据进行研究。
Value Health. 2020 May;23(5):625-631. doi: 10.1016/j.jval.2020.01.007. Epub 2020 Mar 6.
10
Precise and accurate power of the rank-sum test for a continuous outcome.秩和检验对连续结局的精确性和准确性。
J Biopharm Stat. 2020 Jul 3;30(4):639-648. doi: 10.1080/10543406.2020.1730866. Epub 2020 Mar 4.